Dialysis Modalities and HDL Composition and Function.
Lipid abnormalities may have an effect on clinical outcomes of patients on dialysis. Recent studies have indicated that HDL dysfunction is a hallmark of ESRD. In this study, we compared HDL composition and metrics of HDL functionality in patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) with those in healthy controls. We detected a marked suppression of several metrics of HDL functionality in patients on HD or PD. Compositional analysis revealed that HDL from both dialysis groups shifted toward a more proinflammatory phenotype with profound alterations in the lipid moiety and protein composition. With regard to function, cholesterol efflux and anti-inflammatory and antiapoptotic functions seemed to be more severely suppressed in patients on HD, whereas HDL-associated paraoxonase activity was lowest in patients on PD. Quantification of enzyme activities involved in HDL metabolism suggested that HDL particle maturation and remodeling are altered in patients on HD or PD. In summary, our study provides mechanistic insights into the formation of dysfunctional HDL in patients with ESRD who are on HD or PD.
Institute of Experimental and Clinical Pharmacology.
Michael
M
Holzer
Clinical Division of Nephrology, Department of Internal Medicine.
Gernot
G
Schilcher
Institute of Experimental and Clinical Pharmacology.
Sanja
S
Curcic
Institute of Experimental and Clinical Pharmacology.
Markus
M
Trieb
Clinical Division of Cardiology, Department of Internal Medicine, and.
Senka
S
Ljubojevic
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; and.
Tatjana
T
Stojakovic
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; and.
Hubert
H
Scharnagl
Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Chantal M
CM
Kopecky
Clinical Division of Nephrology, Department of Internal Medicine.
Alexander R
AR
Rosenkranz
Institute of Experimental and Clinical Pharmacology.
Akos
A
Heinemann
Institute of Experimental and Clinical Pharmacology, gunther.marsche@medunigraz.at.
Gunther
G
Marsche
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000378:metabolism; D000368:Aged; D043303:Aryldialkylphosphatase / Q000378:metabolism; D016022:Case-Control Studies; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins / Q000097:blood; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000201:enzymology / Q000628:therapy*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008071:Lipoprotein Lipase / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood* / Q000737:chemistry* / Q000494:pharmacology; D008264:Macrophages / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D010530:Peritoneal Dialysis; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood; D049294:Phospholipid Transfer Proteins / Q000097:blood; D006435:Renal Dialysis / Q000379:methods*; D014280:Triglycerides / Q000097:blood
C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008070:Lipopolysaccharides; D008075:Lipoproteins, HDL; D016328:NF-kappa B; C493430:PLTP protein, human; D049294:Phospholipid Transfer Proteins; D014280:Triglycerides; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D008071:Lipoprotein Lipase; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D043303:Aryldialkylphosphatase
cardiovascular disease; hemodialysis; lipids; peritoneal dialysis